Voloridge Investment Management
VKTX icon

Voloridge Investment Management’s Viking Therapeutics VKTX Stock Holding History

Voloridge Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-358,660
Closed -$11.7M – 1096
2026
Q1 		$11.7M Buy
358,660
+166,296
+86% +$5.34M 0.05% 465
2025
Q4 		$6.77M Buy
192,364
+150,212
+356% +$5.32M 0.02% 686
2025
Q3 		$1.11M Buy
+42,152
New +$1.26M ﹤0.01% 1027
2025
Q2 		– Sell
-319,211
Closed -$7.71M – 1400
2025
Q1 		$7.71M Buy
+319,211
New +$10.1M 0.03% 648
2023
Q3 		– Sell
-249,724
Closed -$4.05M – 1617
2023
Q2 		$4.05M Sell
249,724
-145,043
-37% -$3.04M 0.02% 749
2023
Q1 		$6.57M Buy
+394,767
New +$4.08M 0.03% 586
2019
Q1 		– Sell
-20,991
Closed -$161K – 1070
2018
Q4 		$161K Buy
20,991
+8,553
+69% +$102K 0.01% 390
2018
Q3 		$217K Buy
+12,438
New +$148K ﹤0.01% 279

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Voloridge Investment Management's VKTX Position: Q2 2026 in Review

Voloridge Investment Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 358,660 shares — an estimated $11.7M sold.

Voloridge Investment Management first reported a position in VKTX in Q3 2018 and held it in 8 quarters. The position peaked at $11.7M in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Voloridge Investment Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 358,660 Viking Therapeutics shares in Q2 2026, an estimated $11.7M.
  • Voloridge Investment Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 8 quarters.
  • Voloridge Investment Management's Viking Therapeutics position peaked at $11.7M in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.